ExpreS2ion Biotech

ExpreS2ion Biotech is a clinical-stage biopharmaceutical company specializing in the development of complex proteins for vaccines and diagnostics. The company utilizes its proprietary ExpreS2 platform, a non-viral Drosophila S2 insect cell expression system, to produce recombinant proteins with high efficiency and correctness. Their pipeline focuses on infectious diseases and oncology, notably featuring a HER2-targeting breast cancer vaccine and multiple malaria vaccine candidates developed in collaboration with the University of Oxford. ExpreS2ion also operates through its joint venture, AdaptVac, which utilizes virus-like particle (VLP) technology to enhance immunogenicity. The company is headquartered in Denmark and listed on the Nasdaq First North Growth Market in Sweden.